Testosterone drugs under FDA review

Share this article:
From an ad for AbbVie's AndroGel
From an ad for AbbVie's AndroGel

The FDA is giving testosterone therapy a second look. The regulator announced Friday that two studies have prompted it to review the impact of these drugs to see whether the treatments were associated with an increased risk of stroke, heart attack and death. The regulator was already monitoring the situation, but said in a statement that this latest move is meant to “reassess this safety issue.”

The assessment could affect drugs such as AbbVie's market leader AndroGel and Lilly's Axiron.

The studies of note include a Veterans Affairs study of men who had low serum testosterone, an average age of 60 and underlying cardiovascular disease. The study indicated testosterone upped the risk of heart issues and death by around 30%.

A second study of older and younger men with pre-existing heart disease found the risk of heart attack doubled among this patient group for men who were at least 65 years old and on testosterone therapy.

While sales of AbbVie's AndroGel declined almost 21% in the fourth quarter, to $289 million, and slid just over 10% to slightly over $1 billion for the year, it is still a presence on the balance sheet. Lilly's Axiron first hit pharmacies in 2011. The company did not tease out the drug's financial performance in last week's fourth-quarter or annual tallies, but Bloomberg noted in November that expectations were for Axiron prescriptions to bring in around $168 million in year-end sales for the Indianapolis, IN, drugmaker.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...